Yifeng Pharmacy released its 2026 interim report, showing first-half net profit attributable to the parent of 964 million yuan, up 9.5% year on year. Operating revenue was 12.13 billion yuan, up 3.5% year on year; non-GAAP net profit attributable to the parent was 952 million yuan, up 11.1% year on year; net operating cash flow was 1.454 billion yuan, down 7.4% year on year; earnings per share were 0.7949 yuan. In the second quarter, operating revenue was 6.04 billion yuan, up 5.8% year on year, and net profit attributable to the parent was 464 million yuan, up 7.8% year on year. As of the end of the second quarter, total assets were 25.829 billion yuan, down 5.9% from the end of the previous year, and net assets attributable to the parent were 12.118 billion yuan, up 4.2% from the end of the previous year. During the reporting period, the company opened 211 self-operated stores, acquired 11 stores, added 263 new franchise stores, and closed 77 stores, bringing the total number of stores to 15,239, including 4,576 franchise stores. The company said there had been no material change in its operating conditions, and that it would continue to focus on the pharmaceutical retail business while actively expanding into emerging areas such as chronic disease management and internet healthcare.
Yifeng PharmacyFirst-half net profit up 9.5% and revenue up 3.5%, indicating solid financial performance.
